Dr. Reddy's Laboratories Ltd.
8-2-337, Road No. 3, Banjara Hills,
Hyderabad – 500 034, Telangana,
India.
CIN : L85195TG1984PLC004507
T: +91 40 4900 2900
F: +91 40 4900 2999
Email: shares@drreddys.com
www.drreddys.com

July 2, 2021

National Stock Exchange of India Ltd.
"Exchange Plaza"
Bandra-Kurla Complex, Bandra (East),
Mumbai – 400 051
Fax Nos.: 022-26598120/ 26598237/
26598238

Scrip Code: DRREDDY-EQ

Dear Sirs,

Ref.: Your email dated July 01, 2021
Sub: Clarification /Confirmation on news item appearing in "Media/Publication"

This is with reference to your email dated July 1, 2021, seeking clarification/confirmation on news item appearing in the "Website-www.economictimes.com" dated July 01, 2021 captioned "Dr Reddy's Labs denied approval for final trial of Russian-made Sputnik Light".

In this regard, we would like to state that on Wednesday June 30, 2021, the subject expert committee (SEC) deliberated on the submission for Marketing Authorisation of Sputnik Light in India from Dr. Reddy's Laboratories Limited (the Company). The Company presented to the SEC, interim safety and efficacy data from the Phase I/II clinical trial of Sputnik Light in Russia, along with a clinical trial protocol for a Phase III trial of Sputnik Light in India.

In view of the fact that (1) Sputnik Light is the first dose component of Sputnik V, and the Company has already generated safety and immunogenicity data on the first dose component in India through its clinical trial and; (2) a phase III efficacy trial is currently underway in Russian on Sputnik Light, the SEC recommended that:

- The Company should submit safety, immunogenicity and efficacy data from the phase III clinical trial of Sputnik Light in Russia to the SEC for its consideration of Marketing Authorisation of Sputnik Light in India.
- Further, the SEC also observed that in view of the safety and immunogenicity data already generated by the Company in India on the first dose component of Sputnik V (in other words, Sputnik Light), there seems to be inadequate data and justification in conducting a separate similar trial.

In this regard, we would like to state that such communications are in the ordinary course of the Company's business and hence we do not have a practice of disclosing such communications.

The Company would further like to clarify that it has always complied with its reporting obligations under SEBI (LODR) Regulations, 2015, in a timely manner, and will continue to do so.

This is for your information and record.

With regards,

SANDEEP PODDAR

Digitally signed by SANDEEP PODDAR
DN: c=IN, o=Personal, pseudonym=5baa65b04542ac0f9e3878c9d91f0db36d0548a0, 2.5.4.20=bfda99c592e4dc5b7a2e12970b9505d6d51634ab609953e7b6cd73ea7af49394, postalCode=500084, st=TELANGANA, serialNumber=8185d5106ea0d6196f14ae660c09bac334f5ebc1a1790e158f29af33bf208cac, cn=SANDEEP PODDAR
Date: 2021.07.02 08:02:26 +05'30'

Sandeep Poddar
Company Secretary